11 results about "Diclofenac Acid" patented technology

Disclosed are instillable compositions in the form of aqueous solutions comprising hyaluronic acid or a salt thereof and a complex of diclofenac or a salt thereof with 2-hydroxypropyl-beta- cyclodextrin and use thereof in the prevention of urinary tract infections.

Pharmaceutical compositions for topical use containing diclofenac in the form of salt with epolamine, present at concentrations higher than 2.0% by weight are described. Such compositions provide, with respect to those currently available, a more complete absorption of the administered dose, reducing the dispersion of active ingredient and allowing treatments requiring the administration of high and accurate dosages to be carried out.

The invention discloses a method for detecting N-nitrosodiethylamine in diclofenac epolamine, which comprises the following steps: dissolving a diclofenac epolamine sample in a methanol solution, adding a formic acid aqueous solution, mixing, and precipitating out diclofenac epolamine in the sample; centrifugally separating, and taking supernate; and carrying out quantitative detection on the N-nitrosodiethylamine in the supernate by adopting a liquid chromatography-tandem mass spectrometry method. Based on the principle that diclofenac is converted into free acid to be precipitated under the acidic condition, 2% formic acid is creatively selected as a precipitator, matrix interference of main components is effectively removed, the problem that the main components are separated out in a chromatographic system is solved, and a mass spectrometer is protected. According to methodology verification, the method disclosed by the invention is extremely high in sensitivity, good in accuracy, strong in reproducibility, rapid in analysis and good in durability. The method provides a reliable and efficient detection means for quality control of trace N-nitrosodiethylamine in the diclofenac epolamine bulk drug, and has extremely high practical value.

The invention discloses a drug design strategy for releasing hydrogen sulfide based on enzymolysis of thiocarbonyl and application of the drug design strategy in diclofenac drug modification, according to the hydrogen sulfide prodrug, an existing drug with a carboxylic acid structure is vulcanized to form a thiocarboxylic acid structure, and the thiocarboxylic acid structure can release H2S under the enzyme catalysis condition; thiocarboxylic acid can be hydrolyzed by esterase and released to obtain hydrogen sulfide, toxic and side effects of existing drugs are improved by means of anti-inflammation, myocardial protection, gastrointestinal tract protection and the like of hydrogen sulfide, physiological functions of hydrogen sulfide are exerted at the same time, and clinical application of hydrogen sulfide is achieved.

The invention discloses application of magnetic cobalt / nitrogen-doped porous carbon in diclofenac analysis, and belongs to the field of drug residue detection. And performing high-temperature pyrolysis on the precursor ZIF-67 to obtain the magnetic cobalt / nitrogen-doped porous carbon (CNC). The product is used as a magnetic solid-phase extraction adsorbent to separate and enrich diclofenac in a sample to be detected, and is also used as an electrode modification material to amplify an electrochemical signal of diclofenac, then differential pulse voltammetry electrochemical detection is performed, the operation is simple, the reagent consumption is low, and the detection time is short.

A mixture of substances for use in the topical treatment of an oncological hand-foot syndrome, characterized in that the mixture contains the following substances: a. Ibuprofen or diclofenac with a mass fraction of 0.5% to 10% in the mixture; b. Nicotinamide with a mass fraction of 0.5% to 10% in the mixture and c. Tocopherol and / or ascorbic acid with a mass fraction of 0.01% to 10% in the mixture.

The invention relates to the technical field of medicines, and particularly discloses a non-steroidal anti-inflammatory drug choline salt and a preparation method and application thereof. The salt is formed by combining a non-steroidal anti-inflammatory drug and choline; the non-steroidal anti-inflammatory drug in the salt is a component A, a component B or a component C; the component A is S-flurbiprofen; the component B is naproxen; the component C is diclofenac; the molar ratio of S-flurbiprofen to choline is 1: 5-5: 1, the molar ratio of naproxen to choline is 1: 5-5: 1, and the molar ratio of diclofenac to choline is 1: 5-5: 1. According to the non-steroidal anti-inflammatory drug-choline salt successfully prepared by adopting a melting cooling method, the solubility of the non-steroidal anti-inflammatory drug in water is greatly improved, and the non-steroidal anti-inflammatory drug is stable in structure and is not decomposed at normal temperature. According to the medicine salt, the pharmacological activity of the non-steroidal anti-inflammatory medicine is kept, the analgesic activity is improved, and pains such as headache, limb pains, dysmenorrhea, rheumatic arthritis pains and osteoarthritis pains can be rapidly relieved.

To provide a topical pharmaceutical composition containing diclofenac in which crystal precipitation is suppressed. [Solution] A topical pharmaceutical composition comprising (A) one or more selected from the group consisting of loxoprofen, its salts and hydrates thereof, (B) one or more selected from the group consisting of diclofenac, its salts and hydrates thereof, and (C) a lower alcohol, wherein the content of the lower alcohol of (C) is 35% by mass or more and 60% by mass or less based on the total mass of the topical pharmaceutical composition, and the pH of the topical pharmaceutical composition is 5.0 to 7.5.

Composition, in particular pharmaceutical composition, especially for use in the prophylactic and / or therapeutic (symptomatic) treatment of veisalgia (alcohol intoxication, hangover), wherein the composition is in the form of a fixed dosage (fixed dosage form) for oral administration, and wherein the composition comprises an effective, in particular pharmaceutically and / or therapeutically effective, amount of active substances from the drug classes (i) non-steroidal anti-inflammatory drug (NSAID), (ii) H1 antihistamine and (iii) calcium channel antagonist, wherein the active substances are selected from Class (i): Acetylsalicylic acid, ibuprofen, dexibuprofen, flurbiprofen, naproxen, ketoprofen, tiaprofenic acid, diclofenac, indomethacin, acemetacin, flufenamic acid, mefenamic acid, piroxicam, tenoxicam, meloxicam, lornoxicam, nabumetone and / or mixtures thereof, Class (ii): Dimenhydrinate, and Class (iii): Cinnarizine.

The present invention provides a pharmaceutical composition for external use, which contains (a) one or more substances selected from loxoprofen, salts thereof, and hydrates thereof, (b) one or more substances selected from diclofenac, salts thereof, and hydrates thereof, and (d) a lower alcohol, the content of the (d) lower alcohol being 35-60% by mass (inclusive) relative to the mass of the entire pharmaceutical composition for external use. The pH of the external pharmaceutical composition is 5.0 to 7.5. The invention also provides an external pharmaceutical composition. The composition contains (a) one or more substances selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, (b) one or more substances selected from the group consisting of diclofenac, salts thereof, and hydrates thereof, (c) has a hydrocarbon chain structure and a polyoxyethylene polymerization structure, and has a ratio (P / C) of the average number of moles P of the polyoxyethylene chain added to the number of carbons C of the carbon chain of 1.2 or more. And (d) a lower alcohol, the content of the lower alcohol (d) being less than 35 mass%, and the pH being 6.0-8.0.

This invention provides a diclofenac diethylamine latex, belonging to the field of topical pharmaceutical preparations. By adding polyoxyethylene (10) oil-based ether, propylene carbonate, and a natural penetration enhancer to the diclofenac diethylamine latex, this invention obtains a latex with good skin permeability, high bioavailability, and good quality stability, which has significant clinical advantages over existing technologies. The preparation process of the diclofenac diethylamine latex of this invention is simple and very suitable for industrial production.